Literature DB >> 18381506

Toxicity of buprenorphine overdoses in children.

Bryan D Hayes1, Wendy Klein-Schwartz, Suzanne Doyon.   

Abstract

OBJECTIVE: There are few reports in children of overdoses of buprenorphine, a partial opioid agonist used in the treatment of opioid dependence and pain. The purpose of this study was to analyze buprenorphine overdoses in young children reported by US poison centers to the Researched Abuse, Diversion, and Addiction-Related Surveillance System.
METHODS: A retrospective review of buprenorphine overdoses in children < 6 years of age reported to the Researched Abuse, Diversion, and Addiction-Related Surveillance System from November 2002 through December 2005 was performed. Patients lost to follow-up and those ingesting multiple substances were excluded.
RESULTS: Eighty-six cases met inclusion criteria. In the 54 children who developed toxicity, the clinical effects included drowsiness or lethargy (55%), vomiting (21%), miosis (21%), respiratory depression (7%), agitation or irritability (5%), pallor (3%), and coma (2%). There were no fatalities. The mean time to onset of effects was 64.2 minutes, with a range of 20 minutes to 3 hours. Duration of clinical effects was under 2 hours in 11%, 2 to 8 hours in 59%, 8 to 24 hours in 26%, and > 24 hours in 4%. Children who ingested > or = 2 mg of buprenorphine were more likely to experience clinical effects, and all of the children who ingested > 4 mg experienced some effect. No child ingesting < 4 mg experienced a severe effect. Of the 22 children administered naloxone, 67% had at least a partial response.
CONCLUSIONS: Buprenorphine overdoses are generally well tolerated in children, with significant central nervous system and respiratory depression occurring in only 7%. Any child ingesting > 2 mg and children < 2 years of age ingesting more than a lick or taste should be referred to the emergency department for a minimum of 6 hours of observation. Naloxone can be used to reverse respiratory depression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381506     DOI: 10.1542/peds.2007-1774

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  19 in total

1.  Emergency department visits by pediatric patients for poisoning by prescription opioids.

Authors:  Allison Tadros; Shelley M Layman; Stephen M Davis; Rachel Bozeman; Danielle M Davidov
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-11       Impact factor: 3.829

2.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

Review 3.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

Review 4.  Update on the clinical use of buprenorphine: in opioid-related disorders.

Authors:  Simon Ducharme; Ronald Fraser; Kathryn Gill
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

5.  Oxycodone overdose in the pediatric population: case files of the University of Massachusetts Medical Toxicology Fellowship.

Authors:  Katherine L Boyle; Christopher D Rosenbaum
Journal:  J Med Toxicol       Date:  2014-09

6.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

7.  Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Authors:  Sharon L Walsh; Paul A Nuzzo; Shanna Babalonis; Victoria Casselton; Michelle R Lofwall
Journal:  Drug Alcohol Depend       Date:  2016-03-14       Impact factor: 4.492

8.  Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Authors:  Sharon L Walsh; Sandra D Comer; Michelle R Lofwall; Bradley Vince; Naama Levy-Cooperman; Debra Kelsh; Marion A Coe; Jermaine D Jones; Paul A Nuzzo; Fredrik Tiberg; Behshad Sheldon; Sonnie Kim
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

Review 9.  Management of opioid analgesic overdose.

Authors:  Edward W Boyer
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

10.  Supply of buprenorphine waivered physicians: the influence of state policies.

Authors:  Bradley D Stein; Adam J Gordon; Andrew W Dick; Rachel M Burns; Rosalie Liccardo Pacula; Carrie M Farmer; Douglas L Leslie; Mark Sorbero
Journal:  J Subst Abuse Treat       Date:  2014-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.